JP7836087B2 - 腸管免疫異常を原因とする疾患治療薬 - Google Patents

腸管免疫異常を原因とする疾患治療薬

Info

Publication number
JP7836087B2
JP7836087B2 JP2022528841A JP2022528841A JP7836087B2 JP 7836087 B2 JP7836087 B2 JP 7836087B2 JP 2022528841 A JP2022528841 A JP 2022528841A JP 2022528841 A JP2022528841 A JP 2022528841A JP 7836087 B2 JP7836087 B2 JP 7836087B2
Authority
JP
Japan
Prior art keywords
cells
mice
colonic
vagus nerve
intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022528841A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021246399A1 (https=
Inventor
隆典 金井
俊昭 寺谷
洋平 三上
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keio University
Original Assignee
Keio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio University filed Critical Keio University
Publication of JPWO2021246399A1 publication Critical patent/JPWO2021246399A1/ja
Priority to JP2025197174A priority Critical patent/JP2026032059A/ja
Application granted granted Critical
Publication of JP7836087B2 publication Critical patent/JP7836087B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/36053—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for vagal stimulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022528841A 2020-06-01 2021-06-01 腸管免疫異常を原因とする疾患治療薬 Active JP7836087B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025197174A JP2026032059A (ja) 2020-06-01 2025-11-18 腸管免疫異常を原因とする疾患治療薬

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020095241 2020-06-01
JP2020095241 2020-06-01
PCT/JP2021/020821 WO2021246399A1 (ja) 2020-06-01 2021-06-01 腸管免疫異常を原因とする疾患治療薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025197174A Division JP2026032059A (ja) 2020-06-01 2025-11-18 腸管免疫異常を原因とする疾患治療薬

Publications (2)

Publication Number Publication Date
JPWO2021246399A1 JPWO2021246399A1 (https=) 2021-12-09
JP7836087B2 true JP7836087B2 (ja) 2026-03-26

Family

ID=78831133

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022528841A Active JP7836087B2 (ja) 2020-06-01 2021-06-01 腸管免疫異常を原因とする疾患治療薬
JP2025197174A Pending JP2026032059A (ja) 2020-06-01 2025-11-18 腸管免疫異常を原因とする疾患治療薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025197174A Pending JP2026032059A (ja) 2020-06-01 2025-11-18 腸管免疫異常を原因とする疾患治療薬

Country Status (4)

Country Link
US (1) US20230293473A1 (https=)
EP (1) EP4162953A4 (https=)
JP (2) JP7836087B2 (https=)
WO (1) WO2021246399A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522457A (ja) 2002-02-26 2005-07-28 ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003067A1 (en) * 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US8914114B2 (en) * 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
JPWO2007037544A1 (ja) * 2005-09-30 2009-04-16 国立大学法人京都大学 制御性ｔ細胞の製造を向上させる薬剤のスクリーニング方法の開発、及び免疫抑制性のマクロライド系抗生剤を用いる制御性ｔ細胞の製造方法
US20170246267A1 (en) * 2014-08-18 2017-08-31 The Trustees Of Columbia University In The City Of New York Cholinergic antagonism as an adjunct to cancer therapy
EP3405107B1 (en) * 2016-01-20 2023-04-12 Setpoint Medical Corporation Control of vagal stimulation
WO2019005874A1 (en) * 2017-06-26 2019-01-03 The Trustees Of Columbia University In The City Of New York CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
JP2020095241A (ja) 2018-12-10 2020-06-18 京セラドキュメントソリューションズ株式会社 現像装置及び画像形成装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522457A (ja) 2002-02-26 2005-07-28 ノース ショア−ロング アイランド ジューイッシュ リサーチ インスティチュート 脳ムスカリン性レセプターの刺激による炎症性サイトカイン産生の阻害

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DHAWAN, S. et al，Cholinergic receptor activation on epithelia protects against cytokine-induced barrier dysfunction，Acta Physiol，2015年，Vol.213，p.846-859

Also Published As

Publication number Publication date
US20230293473A1 (en) 2023-09-21
EP4162953A4 (en) 2024-10-30
EP4162953A1 (en) 2023-04-12
WO2021246399A1 (ja) 2021-12-09
JP2026032059A (ja) 2026-02-25
JPWO2021246399A1 (https=) 2021-12-09

Similar Documents

Publication Publication Date Title
Teratani et al. The liver–brain–gut neural arc maintains the Treg cell niche in the gut
Sadler et al. Short-chain fatty acids improve poststroke recovery via immunological mechanisms
Wang et al. EGFR-Aurka signaling rescues polarity and regeneration defects in dystrophin-deficient muscle stem cells by increasing asymmetric divisions
Xing et al. Tight junction protein claudin-7 is essential for intestinal epithelial stem cell self-renewal and differentiation
Laranjeira et al. Glial cells in the mouse enteric nervous system can undergo neurogenesis in response to injury
Bicker et al. Neurovascular EGFL7 regulates adult neurogenesis in the subventricular zone and thereby affects olfactory perception
Fan et al. The vascular gene Apold1 is dispensable for normal development but controls angiogenesis under pathological conditions
Šestan et al. Neuronal-ILC2 interactions regulate pancreatic glucagon and glucose homeostasis
Xiong et al. Vi4-miR-185-5p-Igfbp3 network protects the brain from neonatal hypoxic ischemic injury via promoting neuron survival and suppressing the cell apoptosis
Wu et al. Synaptic hyperexcitability of cytomegalic pyramidal neurons contributes to epileptogenesis in tuberous sclerosis complex
US20240076624A1 (en) Methods and Tools for Studying Enteroendocrine Cells
Zhang et al. TMEM25 modulates neuronal excitability and NMDA receptor subunit NR2B degradation
Luo et al. Functional heterogeneity of Wnt-responsive and Hedgehog-responsive neural stem cells in the murine adult hippocampus
Li et al. Peripheral gating of mechanosensation by glial diazepam binding inhibitor
US20160340648A1 (en) Purification of functional human astrocytes
JP7836087B2 (ja) 腸管免疫異常を原因とする疾患治療薬
Yan et al. Role of Cx43 and ACKR3 in Modulating Astrocytic Response and Neuronal Survival Post‐Subarachnoid Hemorrhage
Loreti et al. Tenascin-C from the tissue microenvironment promotes muscle stem cell self-renewal through Annexin A2
Nishina et al. Interleukin-11 is a Marker for Both Cancer-and Inflammation-Associated Fibroblasts that Contribute to Colorectal Cancer Progression
Fonseca Modulation of Intestinal Networks by Neutrophils and Group 3 Innate Lymphoid Cells
Robertson Enteric Glia & the Role of Gpr37 in Intestinal Inflammation
Cosovanu The role of the transcription factor c-Maf in the differentiation and function of intestinal epithelial cells
Kowalkowski Intestinal Atresias and Development with a Focus on the Fibroblast Growth Factor Receptor 2IIIb Mouse Model
Chung et al. IGFBPL1 in DRG Nociceptors Drives Neuropathic Pain and Neuroimmune Crosstalk via IGF1R–ERK Signaling
Schweppe Transcriptional Manipulation of Post-Stroke Axonal Sprouting: A Study of Developmental Transcription Factors Ctip2 and Hhex

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260306

R150 Certificate of patent or registration of utility model

Ref document number: 7836087

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150